Preliminary ProgramApril 15–16, 2010

St. Gallen, Switzerlandwww.ctlag-congress.chCover picture: Urs Anderegg, www.sunGallen.ch

Annual Congress SGAI/SSAI

TRANSLATIONAL IMMUNOLOGY

Neu bei FAUST Laborbedarf AG

ZellkulturflaschenZellkulturröhrchenSerologische PipettenZellkulturschalen

ZentrifugenröhrchenKryoröhrchenVakuumfiltereinheiten

FAUST Laborbedarf AGCH-8201 SchaffhausenTel. 052 630 01 01 · Fax 052 624 02 29info@faust.ch · www.faust.ch

3

Dear Friends, Dear Colleagues

On behalf of the Swiss Society of Allergology and Immunology (SSAI/SGAI),

we cordially invite you to the Annual Congress 2010 at the University of

St. Gallen on April 15–16, 2010.

The bench-to-bedside transition of ground-breaking fi ndings from basic

immunology into clinical practice is rapidly progressing. Among the success

stories in translational immunology are the anti-tumour-necrosis-factor bio-

logicals, and diverse antibodies directed against tumor cells. On the other

hand, research activities in basic immunology are largely fueled by the

demand to better understand and to treat immune-mediated diseases.

Hence, the close interaction of basic and clinical research in immunology

is vital for the progress of our discipline.

The organizing committee together with the program committee has de-

signed a program to promote interactions of basic and clinical scientists who

share interests in translational immunology. The speakers in the plenary lec-

tures, including Paul Kaye (immunopathology of parasitic infection), Jeff Blue-

stone (treating autoimmune diseases), Hans Lassmann (pathogenesis of

neuroimmunological disease), and Aaron Ciechanover, nobel prize laureate

in 2004 (from the proteasome to tumor therapy), will point-out cutting-edge

topics in immunology. Symposia will focus on organ-specifi c immunology

covering diverse themes such of liver immunopathology, skin infl ammation,

immune control in the gut mucosa, tolerance in the CNS, and tumor evasion

from immune recognition. Workshops and Satellite Symposia will provide

time and space for interaction and exchange of knowledge.

The organizers would like to encourage you to actively participate and look

forward to welcome you to this exciting meeting in St. Gallen.

Burkhard Ludewig, president of the organizing committee

Welcome to St. Gallen

4

Thursday, April 15, 2010

08.30–10.00 Registration

Welcome coffee, commercial exhibition

10.00–10.15 Welcome address

10.15–11.00 Plenary lecture I P. Kaye, UK: Immunopathology of leishmaniasis:

lessons for therapeutic vaccination

11.00–11.30 Coffee break, poster viewing, commercial exhibition

11.30–12.30 Symposium 1: Infection and liver immunopathology P. Klenerman, UK

D. Vergani, UK

G. Mieli-Vergani, UK

Symposium 2: Skin infl ammation N. Yawalkar, CH

M. Merad, USA

Symposium 3: Allergic and non-allergic rhinoconjunctivitis S. Lacroix, CH

P. Hellings, B

12.30–14.00 Lunch, poster viewing, commercial exhibition

12.45–13.45 Practitioners Political Forum (SSAI/SGAI)

12.45–13.45 Satellite Symposium: MS Therapy: the past – state of the art – the future(sponsored by Biogen-Dompé AG)

14.00–15.30 Symposium 4: Immune control in the gut mucosa M. Rescigno, I

C. Müller, CH

G. Eberl, F

Symposium 5: Mechanisms of infl ammatory lung disease B. Lambrecht, B

M. Kopf, CH

R. Förster, D

Symposium 6: Differential diagnosis in allergic and autoimmune disorders

E. Laffi tte, CH

B. Balmer, CH

W. Pichler, CH

Program Overview

5

15.30–16.00 Coffee break, poster viewing, commercial exhibition

16.00–17.00 Short communications: Basic Immunology 1 Short communications: Clinical Immunology 1 Short communications: Allergology/Dermatology

17.00–17.15 Break

17.15–18.30 General Assembly SGAI/SSAI

18.30–19.30 Reception at the «Pfalzkeller»

20.00–23.00 Dinner at the «Lagerhaus St. Gallen»

Friday, April 16, 2010

07.30–08.30 Registration, poster viewing, commercial exhibition

08.30–09.15 Plenary lecture II J. Bluestone, USA: Treating autoimmune diseases

09.15–10.00 Plenary lecture III H. Lassmann, A: Infl ammatory diseases of the central nervous system:

Basic and disease specifi c mechanisms of tissue injury

(sponsored by Bayer (Schweiz) AG)

10.00–10.30 Coffee break, poster viewing, commercial exhibition

10.30–12.00 Symposium 7: Tumor evasion from immune recognition T. Blankenstein, D

G. Dranoff, USA

A. Mantovani, I

Symposium 8: Tolerance in the CNS A. Aguzzi, CH

I. Bechmann, D

G. Giovannoni, UK

Symposium 9: Regulation of kidney infl ammation P. Heeger, USA

C. Kurts, D

L. Willcocks, UK

Program Overview

6

12.00–13.30 Lunch, poster viewing, commercial exhibition

12.15–13.15 Satellite Symposium: New perspectives in specifi c immunotherapy (sponsored by Trimedal AG)

13.30–15.00 Symposium 10: Immunology of the synovial membrane (sponsored by ABBOTT AG) C. Pitzalis, UK

W. van Eden, NL

C.M. Weyand, USA

Symposium 11: Biomarkers for novel immunodiagnostics (sponsored by Roche Diagnostics (Schweiz) AG)

K. Lackner, D (invited)

N.N.

N.N.

Symposium 12: In vivo and in situ imaging of immune reactions J. Stein, CH

P. Bousso, F

F. Batisda, UK

15.00–16.00 Short communications: Basic Immunology 2 Short communications: Clinical Immunology 2

16.00–16.15 Short break

16.15–16.30 Poster prices

16.30–17.15 Plenary lecture IV A. Ciechanover, Israel: From the proteasome to tumor therapy

(sponsored by Janssen-Cilag AG)

17.15–17.30 Closing remarks

Program Overview

7

Congress Date April 15–16, 2010

Congress VenueUniversität St. Gallen

Dufourstrasse 50

CH- 9000 St. Gallen

President of the Organizing CommitteeBurkhard Ludewig, Institute of Immunobiology, Cantonal Hospital St. Gallen,

E-mail: burkhard.ludewig@kssg.ch

President of the Swiss Society for Allergology and ImmunologyProfessor Andreas Bircher, MD, Department of Dermatology, University Hospital Basel

Members of the local Organizing CommitteeMark Anliker, St. Gallen

Christoph Driessen, St. Gallen

Silke Gillessen, St. Gallen

Norman Putzki, St. Gallen

Jan-Abel Tasman, St. Gallen

Michael Torzewski, St. Gallen

Members of the Scientifi c CommitteeCezmi Akdis, Davos

Mübeccel Akdis, Davos

Martin Brutsche, St. Gallen

Thomas Cerny, St. Gallen

Daniel Legler, Kreuzlingen

Christa Meyenberger, St. Gallen

Annette Oxenius, Zürich

Jens Stein, Bern

Pietro Vernazza, St. Gallen

Johannes von Kempis, St. Gallen

Administrative Congress OrganizationConvention Team Lucerne AG, Oberseeburg 10, 6006 Luzern

Tel. +41 41 371 18 60, Fax +41 41 371 18 61, E-mail ctlag@bluewin.ch

General Information

8

Important deadlineAbstract: January 15, 2010, at the latest

Hotel reservation: February 10, 2010

Early registration: until March 1, 2010

Congress languageEnglish (no simultaneous translation)

Credits for two days (April 15–16, 2010)Swiss Society of Dermatology and Venereology 16 credits

Swiss Society for Allergology and Immunology 13 credits

Swiss Society of Medical Oncology 11 credits, cat B

Swiss Society of Pneumology 1,5 credits

Swiss Federal Veterinary Offi ce 1,5 days

Registration fees before 1.3.2010 after 1.3.2010

Members SSAI CHF 200.– CHF 250.–

Non-members SSAI CHF 260.– CHF 310.–

Assistant doctors/PhD students CHF 150.– CHF 180.–

Gala dinner CHF 120.– CHF 120.–

Method of paymentPayments should be made by either

Banktransfer to (free of charge)

Bank: UBS AG, CH-6002 Lucerne (BC 248)

Benefi ciary: Convention Team Lucerne AG

Account: 0248-469471.04D

Remark: SGAI 2010

IBAN: CH950024824846947104D

BIC: UBSWCHZH80A

Credit cards VISA, MasterCard

General Information

9

RegistrationPlease use the enclosed registration form and return it before March 1, 2010.

After receipt of the registration fee, you will receive a written confi rmation.

(Download form from www.ctlag-congress.ch or online registration possible.)

CancellationCancellations until March 1, 2010: Refund of total amount paid minus CHF 50.– per person

for administrative charges. No refund after this date. Cancellations must be written to the

administrative congress organization.

Hotel accommodationPlease use the hotel reservation form for accommodation as early as possible.

Reservations should be made by February 10, 2010 at the very latest (download form from

www.ctlag-congress.ch). After this date accommodations will not be available in the vicinity

of the congress venue. To guarantee your reservation we kindly ask you to indicate your credit

card and number on the registration form.

AbstractsAbstracts for oral or poster presentations can be submitted on our website (www.ctlag-

congress.ch). Abstracts sent by post, fax or e-mail will not be accepted. The decision of the

Scientifi c Committee as well as further information will be communicated to the authors by

February 15, 2010.

Deadline for submission: January 15, 2010.

PostersPosters will be exhibited in the poster area from Thursday to Friday

(size of posters: 100 cm × 160 cm (width × hight).

Industry exhibitionThe technical exhibition, located in the main congress area at the University of St. Gallen

will be open from Thursday, 08.30 to Friday, 17.30.

Public transportFrom the main station: take bus no 5 in direction to «Rotmonten» until stop «Universität».

ParkingThere are no parking possibilities at the University areal.

General Information

10

PricesSGAI-Price: the poster award in the amount of CHF 1000.– will be given to the fi rst authors

of the best posters in the categories «Basic Immunology», «Clinical Immunology» and

«Allergology/Dermatology».

Brunello Wüthrich Allergy Poster Price (CHF 1000.–) will be awarded to an original and

interesting allergy case description or casuistics.

Sponsors

The Scientifi c and Organizing Committee wish to acknowledge the fi nancial support of the

following companies and institutions (up-date until 20.10.2009):

Gold Sponsors Basilea Pharmaceutica International AG

Novartis Pharma Schweiz AG

Silver Sponsors ABBOTT AG

Becton Dickinson AG

Faust Laborbedarf AG

UCB Pharma AG

Sponsors Bayer (Schweiz) AG

Biogen-Dompé AG

CBI Medical Products

Janssen-Cilag AG

Staatskanzlei St. Gallen

Stadt St. Gallen

Roche Diagnostics (Schweiz) AG

Ruwag Handels AG

Trimedal AG

General Information

I520,A

ugust2009

A

Mehr LEBENSQUALITÄT bei allergischemAsthma dank Anti-IgE-Therapie!1

Kassenzulässig*

Referenzen:1. Humbert M, Beasley R, Ayres J, et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy, 2005Mar;60(3):309-16. *Kassenzulässig mit folgender Limitierung: "Schweres, gegenüber anderen Therapien resistentes, allergisches Asthma unter der Voraussetzung, dass die Behandlung durch einen Spezialarzt (Pneumologen, Allergologen) erfolgt.Die Weiterbehandlung des Patienten durch einen Grundversorger bedarf der Bewilligung des Vertrauensarztes der Krankenkasse." (gemäss Verfügung BAG vom 16.11.2006).

KurzfachinformationXOLAIR® (Omalizumab). Z: Omalizumab; Stechampulle mit Pulver 150mgOmalizumab und Lösungsmittel zur Herstellung einer Injektionslösung. I: In Kombinationmit anderen Asthmatherapien zur verbesserten Asthmakontrolle bei Erwachsenenund Jugendlichen (ab 12 Jahren) mit schwerem persistierendem allergischem Asthma (positiver Hauttest oder in vitro-Reaktivität gegen ein ganzjährig auftretendes Aeroallergen), falls diese trotz täglicher Therapie mit hoch dosierten inhalativenKortikosteroiden und einem langwirksamen Beta2-Agonisten eine reduzierte Lungenfunktion (FEV1 < 80 %) haben als auch unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und Asthma-Exazerbationen hatten. D:Erwachsene und Kinder ab 12 Jahren: 75 - 375 mg XOLAIR® 1 - 2 x/Monat basierend auf dem IgE-Basis-Wert (I.E./ml) im Serum und des Körpergewichts des Patienten. Einzelheiten s. Arzneimittel-Kompendium der Schweiz®. KI: Überempfindlichkeitgegenüber demWirkstoff oder einem der Inhaltsstoffe. VM: Nicht indiziert zur Behandlung von akuten Asthma-Exazerbationen, akuten Bronchospasmen und Status asthmaticus. Nicht untersucht bei Hyper-Immunglobulin-E-Syndrom, allergischerbronchopulmonaler Aspergillose, Prävention allergischer Reaktionen, atopischer Dermatitis, allergischer Rhinitis, Lebensmittelallergien, Autoimmunerkrankungen, Immunkomplex-vermittelten Zuständen, bestehender Nieren- oderLeberfunktionsstörung. Reduktion von Kortikosteroiden unter ärztlicher Aufsicht. Enthält Saccharose: Patienten mit Diabetes mellitus, Glukose-Galaktose-Malabsorption, Fruktose-Intoleranz, Saccharose-Isomaltase-Mangel müssen darauf hingewiesen werden. Allergische Reaktionen oder lebensbedrohlicheAnaphylaxie und anaphylaktischer Schock können auftreten; Probleme im Zusammenhang mit Immunogenität, parasitären (Wurm-) Infektionen oderMalignitäten können auftreten. Einzelheiten s. Arzneimittel-Kompendium der Schweiz®. IA: Es gibt keine Hinweise auf veränderte Sicherheit durch ande-re i.a. eingesetzten Asthmamedikamente. Die Wirksamkeit der Behandlung in Kombination mit spezifischer Immuntherapie wurde nicht nachgewiesen.UW: Häufig: Kopfschmerzen, Reaktionen an der Injektionsstelle wie Schmerzen, Erythem, Pruritus, Schwellung. Gelegentlich: Schwindel,Schläfrigkeit, Parästhesie, Synkope, orthostatische Hypotonie, Flush, Pharyngitis, Husten, allergische Bronchospasmen, Nausea, Diarrhoe,Dyspepsie, Urtikaria, Rash, Pruritus, Photosensibilität, Gewichtszunahme, Müdigkeit, Anschwellen der Arme, grippeähnliche Symptome. Seltenund sehr selten s. Arzneimittel-Kompendium der Schweiz®. Postmarketing: Anaphylaxie und anaphylaktoide Reaktionen, Alopezie, idiopathischeschwere Thrombozytopenie, allergische granulomatöse Angiitis (d.h. Churg-Strauss-Syndrom), Arthralgie, Myalgie, Gelenkschwellung.Malignitäten, Thrombozyten, Labordaten, Parasitäre Infektionen: s. Arzneimittel-Kompendium der Schweiz®. P: 1 Stechampulle zu 150 mg mit1 Lösungsmittelampulle zu 2 ml: je 1*. Verkaufskategorie: (B). *kassenzulässig. Verkaufskategorie: B. Weitere Informationen entnehmen Siebitte dem Arzneimittel-Kompendium der Schweiz®. ZUL: Novartis Pharma Schweiz AG, Postfach, 3001 Bern. www.novartispharma.ch V2

I520,A

ugust2009 Novartis Pharma Schweiz AG, Postfach, 3001 Bern. www.novartispharma.ch

Add life, add XOLAIR®

Inserat Xolair A5 (d) 01:Inserat Xolair A4 (d) 05 14.8.2009 10:29 Uhr Seite 1

Basilea Pharmaceutica International AG Grenzacherstrasse 487 Postfach CH-4005 Basel www.basilea.com

Inserat_Pre-Launch_A5hoch_cmyk.indd 1 17.09.09 14:18